Kadir Kuğu’s Post

📣We are thrilled to announce that neuroClues is one of the 10 finalists in the Health Tech Challengers, under the Disruptive Diagnosis track! 🌐 Health Tech Challengers is a prestigious platform for digital health startups, giving them the opportunity to showcase how they are shaping the future of healthcare. Out of 10 finalists in each of the 8 digital health tracks, one winner will be chosen based on their pitch, and we are honored to stand alongside such innovative companies. 💥 How is neuroClues disruptive?  Eye movements are the window into the brain. Long before clinical symptoms appear, eye movements can offer clues about neurological health. By providing an objective, quantifiable, and quick way to measure ocular biomarkers, neuroClues could empower clinicians to make more accurate diagnoses—potentially reducing the need for costly and time-consuming tests. 🎯 In essence, we aim to be the stethoscope for the brain. 🙌 A big thank you to Health Tech Challengers and the panel of experts for this recognition. Congratulations to all the other finalists—we’re excited to hear your pitches and learn how your innovations are transforming healthcare! 🚀 And of course, Antoine Pouppez, we can't wait to see you pitch at Health Tech Forward in December, you've got this! #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

📢 The Call for Abstract for #SIME2025 is NOW OPEN! 🔬Share your #research and be a part of the 46th SIME Congress 💡Don’t miss your chance to make an #impact! 🖌️ Submit your #abstract 👉🏻 Link in bio ✨Once you get to know SIME, you’ll never want to leave! #sime2025 #simecongress #aestheticmedicine #sime #46sime #medicalaesthetics #callforabstract #scientific

🌟 Another Ventures&Wine is on its way 🎉 This time, we are diving into AI tools for drug discovery and diagnostics - a brief history from origin to application. Join us for an exhilarating event where we dive deep into the groundbreaking world of Artificial Intelligence and its transformative role in drug discovery, cancer diagnostics, and more. 🧬 What to Expect: Our expert speaker, Michael Green, the CEO of Desupervised and an authority in AI applications, will take us on a captivating journey through the origins and evolution of AI technology. Discover how these innovations are reshaping the landscape of life sciences, accelerating drug development, and revolutionising cancer diagnostics. 🎤 Key Highlights: - The fascinating history of AI and its application in healthcare - Case studies showcasing successful AI applications in drug discovery - Q&A session: Get your burning questions answered! 📅 Date: 10th October 🕒 Time:17:00   📍 Location: Symbion, Fruebjergvej 3, 2100 København Ø Don’t miss this opportunity to gain invaluable insights that could shape the future of medicine! Connect with industry leaders, expand your network, and be part of the conversation that’s driving innovation. 🔗 Register Now: https://lnkd.in/dXBCN8PA Curious to hear more about us? Let's check this 🔍 https://www.rebbls.dk/ Venture&Wine is organised by REBBLS and CPHLabs and supported by Industriens Fond, Københavns Universitet - University of Copenhagen, Symbion Community, HØIBERG - European Patent Attorneys, and VinFraLoire #REBBLSteam #entrepreneurship #AI #LifeSciences #DrugDiscovery #CancerDiagnostics #Innovation #HealthCareTechnology #Networking

It's been a week since the ELRIG UK Drug Discovery conference, and what an event! Reflecting on the insightful discussions, I left with a renewed sense of excitement for the future of our industry. Despite post pandemic turbulence, the conference highlighted the resilience and innovation driving us forward. ⁣ ⁣ 𝐌𝐲 𝐤𝐞𝐲 𝐫𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧𝐬:⁣ ⁣ *𝐈𝐧𝐭𝐞𝐫𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐚𝐫𝐲 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐤𝐞𝐲: the most groundbreaking ideas come when we break down silos. Observing cross-industry partnerships flourish reinforced the power of collaboration in solving the most complex challenges.⁣ ⁣ *𝐇𝐚𝐫𝐧𝐞𝐬𝐬𝐢𝐧𝐠 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 & 𝐀𝐈: From automation to AI-powered platforms, its evident that the future of drug discovery lies in advanced technologies. Great to hear about real-world examples of AI transforming research speed and accuracy, making processes faster and scalable. ⁣ *𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐂𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐅𝐨𝐜𝐮𝐬: At the end of the day, it's all about improving lives. Every session, from early discovery to translational medicine, was a reminder that patients are at the heart of what we do.⁣ ⁣ *𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 & 𝐃𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲: Elrig's commitment to sustainability and fostering diversity stood out. Their push for an inclusive and accessible community reflects their vision of an equitable future in life sciences. #elrigdd24 #reflections #drugdiscovery #srgtalent #AI #diversity #collaboration

🎉 Today we celebrated the conclusion of an almost year long journey within the #10xHealth life science scaleup program, with inspiration from Martin Stenfeldt and Anna Philipson♦️ from Good Accelerator helping the companies reflect on the past year, and putting forward the companies aspirations for the next phase of growth. Martin shared some of the findings of his upcoming book in scaling up life science companies, with interesting conclusions and models for the participants to reflect on.   📈10xHealth is a scaleup program targeting life science growth companies in southern Sweden (Skåne and Blekinge) and is developed by SmiLe Venture Hub and Medicon Village with partial funding from the European Regional Development Fund. The participants of the pilot program 2024 are Iconovo AB, Neola Medical, Uman Sense, Paindrainer AB, NanoEcho AB, and Cyxone.   🚀The next iteration of the program will commence in August 2025, and will be open for applications in January 2025. We welcome Swedish and Danish life science companies who would like to gain insights and supportive tools to help springboard their next stage of growth, within a trusted and interactive peer-to-peer setting.   👉For more information about 10xHealth: https://10xhealth.se/ Or reach out to Christine Dahlman Jacobsen or Sarah Lidé.

Paris-based AI company Bioptimus has secured US $41 million in funding, bringing its total to US $76 million within a year. The round, led by Cathay Innovation, included investors like Sofinnova Partners, Bpifrance, and Hitachi Ventures, supporting its AI-driven biology advancements. #Bioptimus #AIinBiology #TechInnovation #FundingSuccess #CathayInnovation Read more: https://lnkd.in/ddTEJGUs

HJB (a subsidiary of Transcenta) is open to collaborating with partners ranging from startup biotechs to large pharma to expedite R&D and accelerate commercialization. Take a fresh look at its integrated, cutting edge technology platform. #CDMO, #biologics, #technologylicensing, #perfusionsystems

🏎️⚽🏈 Neurotechnology is Revolutionising Elite Sports! 🧠✨ #Neurotechnology is pushing the boundaries of performance in sports like Formula 1, Major League Soccer National Football League (NFL), The Football Association The Premier League and more by using #EEG neurotechnology. Monitoring brain activity in real time provides invaluable insights into focus, reaction times, and fatigue—giving the sport elites the competitive edge they need. #Neurofeedback By harnessing neural data, optimising decision-making, mental resilience, and overall performance, empowering teams and athletes to achieve new levels of success. 📊 The future of elite sports is here—and it’s driven by neurotech! 💥 #Neurotechnology #SportsTech #EEG #AthletePerformance #CognitiveOptimization #Formula1 #Soccer #NFL #Athletics #MentalResilience #Cerebralink #SportsInnovation #PeakPerformance #DataDriven #football #BCI #neurotech José Manuel Muñoz Zak Brown Toto Wolf Christian Horner CBE Lewis Hamilton Lando Norris https://lnkd.in/ex7uMH6J

🌟 Phenotypic drug discovery has delivered transformative therapies—but are we at the start of a new wave or nearing the end of an era? Will emerging tools like AI and advanced imaging, coupled with market shifts like increased open innovation, elevate phenotypic drug discovery to new heights? Or will the high costs of automation limit new players, and cellular models fall short in clinical translation? Share your perspective in an anonymous 3-minute survey on the future of phenotypic drug discovery 🔗 https://lnkd.in/es2Snj7P Results will be unveiled during the Future of Phenotypic Drug Discovery panel at #SLAS2025 in San Diego—and shared with the broader community afterward on LinkedIn. If you're attending SLAS2025 in San Diego, I'll be chairing a panel the morning of January 28th that brings together leaders in Phenotypic Drug Discovery, to discuss where the field is headed. Comment below to learn more or you'd like to meet up at SLAS! #DrugDiscovery #PhenotypicScreening #InnovationInScience #AIInBiotech #SLAS2025 #LifeSciences

@Artificial Intelligence, Deep Learning, Machine Learning